NEW YORK (360Dx) – Cernostics said today that it has raised $2.5 million in a Series A1 financing round.

Illumina Ventures was the sole investor in the round, which will go toward Cernostics' clinical and market development studies for its TissueCypher Barrett's Esophagus assay for predicting the risk of developing esophageal cancer in patients with Barrett's esophagus.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.